The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood ...
The Food and Drug Administration on Thursday granted accelerated approval to a new dual-acting drug from Amgen to treat small cell lung cancer in people whose disease has progressed following ...
The U.S. Food and Drug Administration on Thursday granted accelerated approval to Amgen's tarlatamab, a targeted ...
El jueves, la FDA aprobó el Imdelltra (tarlatamab-dlle) de Amgen Inc (NASDAQ:AMGN) para el tratamiento de pacientes adultos con cáncer de pulmón microcítico de células pequeñas en estadio ...
(Reuters) - The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood disorder treatment Soliris. Amgen's drug will be marketed ...
The approval comes with a black-box warning about the risk of serious infections caused by a bacteria called neisseria meningitidis. Amgen's drug will be marketed under the name Bkemv. Biosimilars ...
El jueves, la FDA aprobó el Imdelltra (tarlatamab-dlle) de Amgen Inc (NASDAQ:AMGN) para el tratamiento de pacientes adultos con cáncer de pulmón microcítico de células pequeñas en estadio avanzado (ES ...
Amgen Inc. (NASDAQ:AMGN) has recently been in the news due to its involvement in the promising obesity drug market. Analysts ...
The U.S. Food and Drug Administration on Thursday approved a new drug to treat patients with an advanced form of deadly lung ...
The Food and Drug Administration last week approved an innovative new treatment for patients with a form of lung cancer. It ...